Foghorn Therapeutics Announces New Preclinical Data for Selective SMARCA2 Inhibitor FHD-909 and Selective CBP and EP300 Degrader Programs at 2025 AACR Meeting
Portfolio Pulse from
Foghorn Therapeutics announced new preclinical data for its drug candidates FHD-909, Selective CBP degrader, and Selective EP300 degrader at the upcoming 2025 AACR Annual Meeting. The company is focusing on developing innovative treatments targeting chromatin regulatory systems, with FHD-909 showing potential in SMARCA4 mutated cancers, particularly non-small cell lung cancer.
March 25, 2025 | 8:45 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Preclinical data presentation at AACR 2025 demonstrates potential of FHD-909 and other drug candidates in targeting specific cancer mutations
The detailed preclinical data presentation and ongoing Phase 1 trial for FHD-909 suggest positive momentum for the company's research pipeline, which could attract investor interest and potentially boost stock performance.
CONFIDENCE 90
IMPORTANCE 85
RELEVANCE 100